Reason for truncation of asparaginase in the main and subcohort
| . | Main cohort, n = 1401, n (% of the cohort) . | Subcohort, n = 1115, n (% of the cohort) . | No AEA,* n . |
|---|---|---|---|
| Clinical hypersensitivity | 208 (14.8) | 157 (14.1) | 139 |
| Pancreatitis | 88 (6.3) | 53 (4.8) | 1 |
| Thrombosis | 24 (1.7) | 14 (1.3) | — |
| Hyperlipidemia | 10 (0.7) | 8 (0.7) | — |
| Liver toxicity | 7 (0.5) | 7 (0.6) | — |
| Other† | 21 (1.5) | 16 (1.4) | — |
| Total no. of truncated patients | 358 (25.5) | 255 (22.9) | 140 |
| Including patients with silent inactivation (truncatedorAEA-) | — | 301 | 186 |
| . | Main cohort, n = 1401, n (% of the cohort) . | Subcohort, n = 1115, n (% of the cohort) . | No AEA,* n . |
|---|---|---|---|
| Clinical hypersensitivity | 208 (14.8) | 157 (14.1) | 139 |
| Pancreatitis | 88 (6.3) | 53 (4.8) | 1 |
| Thrombosis | 24 (1.7) | 14 (1.3) | — |
| Hyperlipidemia | 10 (0.7) | 8 (0.7) | — |
| Liver toxicity | 7 (0.5) | 7 (0.6) | — |
| Other† | 21 (1.5) | 16 (1.4) | — |
| Total no. of truncated patients | 358 (25.5) | 255 (22.9) | 140 |
| Including patients with silent inactivation (truncatedorAEA-) | — | 301 | 186 |